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Purpose
Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of pacli-
taxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol
plus carboplatin for ovarian cancer treatment. 
Materials and Methods
In this multicenter, randomized, phase II study, patients with International Federation of 
Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to
receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carbo-
platin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and
Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). 
Results
Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages
were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median follow-
up was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval
[CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (non-
inferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3
to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550).
Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0%
vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p=
0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All
toxicities were manageable.
Conclusion
Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer
demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard
paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and
to investigate long-term outcomes.
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Introduction
Ovarian cancer is the most lethal gynecologic malignancy,
being responsible for approximately 14,000 deaths in the
United States annually [1]. It constitutes 2.1% of cancers
among Korean women [2], and over 70% of patients present
with advanced stage disease. The primary treatment involves
cytoreductive surgery followed by chemotherapy. Standard
chemotherapy for ovarian cancer patients includes 5-7.5 area
under the curve (AUC) of carboplatin combined with 175
mg/m2 of paclitaxel administered for six cycles at 3-week 
intervals in accordance with. Several studies demonstrate
that 175 mg/m2 of paclitaxel combined with 5 AUC of car-
boplatin induces a Response Evaluation Criteria In Solid
Tumor (RECIST) response rate of 59.5%-66% and a carbohy-
drate antigen 125 (CA-125) response rate of 72%-76.8% [3].
Recent reports also show that addition of bevacizumab (a
monoclonal antibody against vascular endothelial growth
factor) to the standard treatment prolongs progression-free
survival but not overall survival (OS) [4]. Despite recent 
exploration of targeted therapies and immunotherapies, 
paclitaxel remains the most important drug in ovarian cancer
treatment. Thus, many researchers are focusing on variations
in the schedule and dosage with the aim of enhancing pacli-
taxel’s effect. The current trend is to use dose-dense weekly
paclitaxel therapy; however, the effects are controversial and
such treatment is associated with a higher rate of severe sen-
sory neuropathy [5,6]. 
To enhance the solubility of the hydrophobic paclitaxel
compound, it is prepared using polyoxyl-35-castor oil (Cre-
mophor EL; CrEL). However, CrEL causes hypersensitivity
reactions [7]. Even with premedication, paclitaxel-CrEL treat-
ment causes minor hypersensitivity reactions in 10%-44% of
patients, and potentially life-threatening reactions in 1%-3%
of patients [8,9]. 
Genexol-PM (Samyang Co., Seoul, Korea) is a novel bio-
degradable polymeric micellar formulation of paclitaxel. In
vivo, Genexol-PM shows greater antitumor activity and
higher concentrations in tumor tissues compared to conven-
tional paclitaxel [10]. Dose-limiting toxicities of Genexol-PM
include neuropathy, myalgia, and neutropenia. Two phase I
trials have tested Genexol-PM in advanced cancers; the trial
performed in the United States reported a maximum toler-
ated dose (MTD) of 435 mg/m2, and the trial in Korea
showed an MTD of 390 mg/m2. Accordingly, a Genexol-PM
dose of 300 mg/m2 was recommended for phase II studies,
which is higher than the recommended dose of CrEL-based
paclitaxel (175 mg/m2) [11]. A phase I clinical trial was per-
formed in Korea to investigate combination therapy with
Genexol-PM plus carboplatin as a first-line treatment for
ovarian cancer [12]. Although the MTD of Genexol-PM was
not determined, a dosage of 260 mg/m2 was recommended
for phase II trials. 
Our present open-label, randomized, phase II study aimed
to evaluate the efficacy and safety of first-line treatment with
Genexol-PM plus carboplatin administered every 3 weeks in
patients with epithelial ovarian cancer, compared to treat-
ment with conventional CrEL-based paclitaxel (Genexol,
Samyang Co.) plus carboplatin. Our results revealed that
Genexol-PM was non-inferior to Genexol, and that Genexol-
PM showed well-tolerated toxicities compared with the stan-
dard paclitaxel regimen. This trial was registered with Cli-
nicalTrials.gov, number NCT01276548.
Materials and Methods
1. Patient population
We performed a multicenter randomized, open-label, con-
firmatory phase II clinical trial in patients diagnosed with 
epithelial ovarian cancer (International Federation of Gyne-
cology and Obstetrics [FIGO] IC-IV at diagnosis) at 10 insti-
tutions in Korea. This trial was designed to compare efficacy
and safety between carboplatin combined with Genexol-PM
and carboplatin combined with Genexol. The included 
patients had undergone debulking surgery without previous
chemotherapy for treatment of epithelial ovarian cancer that
was measurable on imaging according to the RECIST ver. 1.0
[13], or that showed CA-125 levels of over twice the upper
limit of normal within 7 days or at two tests before starting
study treatment. Additional inclusion criteria were an East-
ern Cooperative Oncology Group (ECOG) performance sta-
tus of 0-2, adequate organ function, and being deemed
appropriate receive paclitaxel and carboplatin for ovarian
cancer treatment. Exclusion criteria were medical history of
central nervous system disorder, current uncontrolled med-
ical conditions that could interfere with the patient’s ability
to undergo study treatment, preexisting sensory or motor
neuropathy over grade 1 according to National Cancer Insti-
tute Common Toxicity Criteria (NCI CTCAE), and history of
chemotherapy for the ovarian cancer.
All participants gave their written informed consent. The
study protocol was approved by the appropriate institutional
review boards and independent ethics committees, and was
in compliance with Good Clinical Practice, Guidelines of the
International Conference on Harmonization, and the Decla-
ration of Helsinki. 
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2. Treatment
The enrolled patients were randomly assigned (1:1) to a
treatment group, with stratification according to disease sta-
tus after debulking surgery in the primary setting. Either
Genexol-PM and carboplatin or Genexol and carboplatin
were administered on day 1 of each 3-week cycle. Drug 
administration began within 4 days after randomization, and
was continued for a maximum of six cycles or until the 
investigator detected disease progression, the subject rejected
the administration, or dose-limiting toxicity occurred. On
day 1 of each cycle, Genexol-PM or Genexol was intra-
venously administered over 3 hours, followed by carboplatin
administration for 30-60 minutes. Genexol-PM administra-
tion began at a dose of 260 mg/m2, Genexol was adminis-
tered at a dose of 175 mg/m2, and the carboplatin dosage was
5 AUC. The Genexol-PM dosage could be increased to 300
mg/m2 starting in cycle 2 if the patient did not experience a
non-hematologic adverse drug reaction of > grade 2 from the
first cycle. To minimize hypersensitivity, Genexol-PM or
Genexol administration was preceded by premedications, 
including dexamethasone and H2-blockers.
3. Assessments
The primary efficacy outcome was the estimated compos-
ite CA-125 and RECIST response rate for each treatment
group. The RECIST response rate is defined as the proportion
of subjects with a measurable disease who show complete or
partial response. The overall response was determined based
on tumor response evaluation of target and non-target 
lesions after every two cycles. Tumor response and overall
response were evaluated according to RECIST criteria [13].
CA-125 response rate was defined as the proportion of sub-
jects with CA-125 response [14], which was evaluated based
on responses from the initial administration to the last cycle.
Shin-Wha Lee, Phase II Trial of Genexol-PM in Ovarian Cancer
Fig. 1. Analyzed patient populations. ITT, intention-to-treat; PP, per-protocol.
Subjects of clinical trial (n=102)    
  Genexol-PM+carboplatin (n=51)
  Genexol+carboplatin (n=51)
No use of the study drug or comparator (n=4)    
  Genexol-PM+carboplatin (n=1)
  Genexol+carboplatin (n=3)
Subjects eliminated during screening (n=29)    
Reason of elimination
- Consent withdrawn (n=1)
- Violation of inclusion/exclusion criteria (n=28)
Discontinued subjects (n=11)    
Reason of discontinuation
  Genexol-PM+carboplatin 
  - Consent withdrawn (n=0)
  - Major protocol violation (n=0)
  - Investigator's discretion (n=1)
  - Other (n=4)
  - Violation of inclusion/exclusion criteria (n=0)   
  Genexol+carboplatin 
  - Consent withdrawn (n=2)
  - Major protocol violation (n=4)
  - Investigator's discretion (n=0)
  - Other (n=0)
  - Violation of inclusion/exclusion criteria (n=0)
Subjects who used the investigational products 
at least once (n=98) (ITT population)  
  Genexol-PM+carboplatin (n=50)
  Genexol+carboplatin (n=48)
Subjects who completed the trial (n=87) 
(PP population)  
  Genexol-PM+carboplatin (n=45)
  Genexol+carboplatin (n=42)
Participants (n=131)
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Each cycle included laboratory testing and assessment of
ECOG performance status. Adverse events were graded fol-
lowing the National Cancer Institute’s CTCAE ver. 3.0.
4. Statistical analysis
The primary efficacy outcome was the CA-125 and RECIST
composite response rate defined as the fraction of patients
who showed complete responseor partial responsebased on
RECIST ver. 1.0 and/or a CA-125 response. The predefined
non-inferiority margin was an absolute difference of 16.3%
in the primary endpoint. A one-sided 95% upper confidence
limit of the difference in the objective response rate between
the Genexol-PM group and the Genexol group that was
below the threshold of non-inferiority was considered to 
indicate that the Genexol-PM group not inferior to the
Genexol group. Secondary efficacy outcomes included time
to progression (TTP) and OS. Categorical variables were 
analyzed using the chi-square test, and non-parametric vari-
ables with the Wilcoxon rank-sum test. Survival curve analy-
sis was performed using the Kaplan-Meier method, and
between-group differences were evaluated with the log-rank
method. We also analyzed safety and efficacy endpoints
among patients in each group who received at least one dose
of study treatment. All statistical analyses were performed
using SPSS ver. 21 (IBM Corp., Armonk, NY), and applying
a two-sided significance level of 5%.
Results
1. Patient characteristics
From August 2009 to May 2012, this study enrolled 131 
patients with epithelial ovarian cancer, 29 patients dropped
out of the screening because most of them did not meet the 
inclusion criteria, especially for CA-125 level more than twice
the upper limit of normal after debulking surgery. Except for
four patients who withdrew their consent after randomization,
98 patients were included in the analyses of clinical efficacies
and safety (Fig. 1). Mean patient age was 56.4 years (±10.8
years) in the Genexol-PM group, and 55.2 years (±8.9 years) in
the Genexol group (p=0.554) (Table 1). The two groups did not
significantly differ with regards to histopathologic grade or
FIGO stage. Over 80% of the overall subjects had a histopatho-
logical grade of G3 (poorly differentiated) or G2 (moderately
differentiated). FIGO stages at diagnosis were IIIC for 38 
patients (76.0%) in the study group and 31 patients (64.6%) in
Cancer Res Treat. 2018;50(1):195-203
Table 1. Patient characteristics
Characteristic Genexol-PM+carboplatin Genexol+carboplatin p-value(n=50) (n=48)
Age (yr) 56.4±10.8 55.2±8.9 0.554 
Histopathological grade
GX 1 (2.0) 0 ( 0.129 
G1 2 (4.0) 0 (
G2 17 (34.0) 10 (20.8)
G3 25 (50.0) 35 (72.9)
G4 1 (2.0) 0 (
Unknown 4 (8.0) 3 (6.3)
FIGO stage
IC 1 (2.0) 0 ( 0.508 
IIIA 1 (2.0) 1 (2.1)
IIIB 1 (2.0) 1 (2.1)
IIIC 38 (76.0) 31 (64.6)
IV 9 (18.0) 15 (31.3)
Disease after surgery
Measurable disease 41 (82.0) 40 (83.3) 0.701
Non-measurable disease 9 (18.0) 8 (16.7)
Overall administration cycles 5.62±1.12 5.35±1.60 0.347 
Values are presented as mean±standard deviation or number (%). GX, differentiation cannot be assessed; G1, well differenti-
ated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; FIGO, International Federation of Gyne-
cology and Obstetrics. 
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the control group, and IV for nine patients (18.0%) in the study
group and 15 patients (31.3%) in the control group (Table 1).
The mean number of cycles was 5.62±1.12 in the Genexol-PM
group and 5.35±1.60 in the Genexol group. In the Genexol
group, two subjects had their dose reduced once. The mean
doses administered were 260.00±0.00 mg/m2 of Genexol-PM
and 5.00±0.00 AUC of carboplatin in the study group, and
174.24±3.81 mg/m2 of Genexol and 5.00±0.00 AUC of carbo-
platin in the control group.
2. Efficacy
The study group (Genexol-PM+carboplatin) showed a 
CA-125 and RECIST composite overall response rate (ORR) of
88.0%, with a 95% confidence interval (CI) of 80.4-95.6. The
control group (Genexol+carboplatin) showed a CA-125 and
RECIST composite ORR of 77.1% (95% CI, 67.1 to 87.1). The
between-groups difference in ORR was $10.9%, which was
not statistically significant (p=0.701), and was lower than the
non-inferiority threshold (16.3%), indicating that the Genexol-
Shin-Wha Lee, Phase II Trial of Genexol-PM in Ovarian Cancer
Genexol-PM+carboplatin (n=50)            Genexol+carboplatin (n=48)Response rate
No. (%) or median 95% CI No. (%) or median 95% CI
p-value
Overall responsea) 44 (88.0) 80.4-95.6 37 (77.1) 67.1-87.1 0.701
CR 24 (48.0) 16 (33.3)
PR 20 (40.0) 21 (43.8)
SD 3 (6.0) 5 (10.4)
PD 0 ( 1 (2.1)
NE 3 (6.0) 4 (8.3)
Survival rate
Time to progressionb) 14.8 ( 11.3-20.2 15.4 ( 13.2-29.6 0.546
Overall survivalc) (–) (–) 0.100 
Table 2. Responses and survival rates
CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progrssive disease; NE, not evaluated.
a)Threshold of non-inferiority: 16.3%, b)Genexol-PM+carboplatin censored: 30, Genexol+carboplatin censored: 30, c)Genexol-
PM+carboplatin censored: 45, Genexol+carboplatin censored: 47.
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PM was not inferior to Genexol (Table 2).
The median follow-up period was 18.0 months (range, 6.1
to 33.8 months). Tumor progression was detected in 20 
patients in the Genexol-PM group, and 18 patients in the
Genexol group. One patient in each group died from tumor
progression. Median TTP was 14.8 months (95% CI, 11.3 to
20.2) in the Genexol-PM group and 15.4 months (95% CI, 13.2
to 29.6) in the Genexol group (p=0.550) (Fig. 2A). Deaths 
occurred among five subjects in the study group and one sub-
ject in the control group; however, OS with 50% mortality was
not calculated. We found no significant between-groups dif-
ference in survival (p=0.100) (Fig. 2B). We analyzed the con-
cordance between the two response rates among subjects
evaluated for both CA-125 and RECIST responses. In the
Genexol-PM group, 38 patients met the definition of CA-125
response, while a RECIST response was achieved by 35 sub-
jects. In the Genexol group, 33 patients met the definition of
CA-125 response, while the RECIST response was met by 29
patients.
3. Safety
During the study period, 441 adverse events occurred in 50
subjects (100.0%) in the Genexol-PM group, including 49 seri-
ous events (11.1%, 49/441). In the Genexol group, 376 adverse
events occurred in 44 subjects (91.7%), including 40 serious
events (10.6%, 40/376). Except for alopecia, the rates of hema-
tologic and nonhematologic adverse events did not signifi-
cantly differ between the two groups. Neutropenia occurred
in 43 patients (86.0%) in the Genexol-PM group and 37 
patients (77.1%) in the Genexol group (p=0.120), even though
a higher paclitaxel dose was administered in the Genexol-PM
group. In the Genexol-PM group, there were 104 confirmed
instances of hematologic toxicities (23.6%, 104/441) compared
to 77 instances in the Genexol group (20.5%, 77/376). Hyper-
sensitivity reactions occurred in seven patients (14.0%) in the
Genexol-PM group, and three patients (6.3%) in the Genexol
group (p > 0.99). Incidences of peripheral neuropathy and
myalgia did not significantly differ according to study treat-
ment. Peripheral neuropathy occurred in 42 patients (84.0%)
in the Genexol-PM group with no serious cases, and in 31 
patients (64.6%) in the Genexol group with one case (2.1%)
considered serious (p=0.148) (Table 3). All reported toxicities
were successfully managed with conservative care, and no
treatment-related deaths occurred in either group. In the
Genexol-PM group, ECOG performance from screening/base-
line to last observation carried forward changed by 0.02±0.68,
which was not statistically significant (p=0.837).
Discussion
Paclitaxel is an important drug in ovarian cancer treat-
ment. However, the commonly used paclitaxel solubilizer
CrEL contributes to severe toxicities, including hypersensi-
tivity reactions and peripheral neuropathies [7,15-18]. To
overcome these toxicities and to potentially improve efficacy,
solvent-free paclitaxel formulations have been developed.
Genexol-PM is a freeze-dried macromolecule micelle of 
paclitaxel that was approved in Korea in 2006 with the indi-
cations of first-line therapy for recurrent and metastatic
breast cancer (MBC) and non-small cell lung carcinoma
(NSCLC). The copolymer mPEG-PDLLA that is used in
Genexol-PM is not listed in the U.S. Pharmacopoeia; how-
ever, the individual polymers mPEG and polylactide are
used in multiple pharmaceutical products and are on the
Food and Drug Administration's Inactive Ingredient List.
The mPEG-PDLLA copolymer has been confirmed to be non-
toxic. Several phase II clinical trials demonstrate that
Genexol-PM is generally well tolerated and shows sufficient
antitumor activity in patients with MBC, NSCLC, and
urothelial carcinoma [19-21]. Phase II clinical trials have been
performed in the United States to examine Genexol-PM
monotherapy for the treatment of progressive pancreatic can-
cer [22]. In Korea, a phase I clinical trial investigated the com-
bination of Genexol-PM with carboplatin in ovarian cancer
patients (featured poster presentation, abstract 0071) [12].
Our present study evaluated the anti-tumor effects of first-
line treatment with Genexol-PM+carboplatin or with Gene-
xol+carboplatin among epithelial ovarian cancer patients,
and demonstrated that the efficacy outcome in the study
group was not inferior to that in the control group. Genexol-
PM plus carboplatin was associated with a CA-125 and 
RECIST composite response rate of 88.0% in intention-
to-treat (ITT) analysis (the primary efficacy outcome), and
93.2% in per-protocol analysis. The primary efficacy outcome
differed between the groups by $10.92%, with a one-sided
95% upper confidence limit of 1.60%, which was below the
non-inferiority threshold (16.3%)—indicating that outcome
with Genexol-PM was not inferior to outcome with Genexol.
As a secondary efficacy outcome, the RECIST response rate
from ITT analysis of subjects with measurable lesions was
85.4% in the Genexol-PM group and 75.0% in the Genexol
group. Among the subjects without measurable lesions, the
CA-125 response rate was 100% in both groups. With regard
to OS rate in the ITT population, five subjects died and 47
subjects were censored in the Genexol-PM group, and one
subject died and 46 subjects were censored in Genexol group.
OS with 50% mortality was not calculated. The between-
group difference in survival was not statistically significant
(p=0.100).
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Higher doses of conventional paclitaxel do not improve 
response rates or survival among patients with MBC, pre-
dominantly due to greater toxicities [23]. On the other hand,
compared to conventional paclitaxel, nanoparticle albumin-
bound (nab) paclitaxel produces higher response rates with
similar safety profiles in cases of MBC, NSCLC, and pancre-
atic cancer [24-26]. However, controversial results are 
reported by several randomized trials investigating the roles
of higher paclitaxel doses in breast cancer treatment [27,28].
No comparative clinical trials have evaluated the efficacy of
high-dose paclitaxel in epithelial ovarian cancer. Our present
phase II trial in ovarian cancer demonstrated the non-inferi-
ority of Genexol-PM but did not show that higher paclitaxel
doses improved efficacy with regards to ORR, TTP, or OS.
Thus, there remains a need for additional clinical trials, par-
ticularly phase III/IV studies in a large number of patients
with ovarian cancer to test the superiority of high-dose
Genexol-PM compared to the conventional dose of pacli-
taxel. This may be a great help in selecting chemotherapeutic
agents as first-line treatment for patients with ovarian can-
cer.
In terms of safety, as expected, the Genexol-PM group
showed higher incidence of neutropenia and lower incidence
of peripheral neuropathy, but in this study, Genexol-PM and
conventional paclitaxel showed similar safety profiles, 
including neutropenia and peripheral neuropathy. Some 
researchers have reported that peripheral neuropathy due to
paclitaxel itself is inevitable, although the solvent-free pacli-
taxel formulation has the advantages of inducing less severe
peripheral neuropathy and more rapid recovery compared
with conventional paclitaxel [24,29]. A randomized trial of
nab-paclitaxel plus gemcitabine versus gemcitabine alone for
treatment of pancreatic cancer found the most notable differ-
ence in adverse events to be the rate of peripheral neuropa-
thy (17% with nab-paclitaxel plus gemcitabine versus 1%
with gemcitabine) [26]. Notably, peripheral neuropathy in
that study was rapidly reversible in most patients, with neu-
ropathy of " grade 3 improved to ! grade 1 in a median of 29
days. In our present study, no patients in the Genexol-PM
group showed peripheral neuropathy of grade 3 or higher.
In conclusion, our present phase II study demonstrated a
non-inferior ORR and manageable toxicities with Genexol-
PM plus carboplatin compared to with standard Genexol and
carboplatin. Genexol-PM allows administration of a greater
paclitaxel dose without compromising patient safety. Over-
all, Genexol-PM with carboplatin seems to be efficacious and
safe as first-line therapy in patients with epithelial ovarian
cancer. Further studies of Genexol-PM are warranted, par-
ticularly to examine the use of different schedules, including
weekly doses, and to study long-term outcomes, including
the reversibility of peripheral neuropathy.
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